<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984477</url>
  </required_header>
  <id_info>
    <org_study_id>D2650C00006</org_study_id>
    <nct_id>NCT00984477</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Exploratory Study to Assess the Pharmacokinetics of Single Oral Doses and a Single Intravenous Radiolabelled Microtracer Dose of AZD5122 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine how quickly AZD5122 is absorbed into and cleared by
      the body when given to healthy, non smoking males at different dose levels. This is a 2 part
      study, in Part B a single group of subjects will be given both an oral dose and intravenous
      microdose of AZD5122 at a specialist unit. For part B there is no placebo treatment given.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile: concentration of AZD5122 in blood</measure>
    <time_frame>Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile: concentration of AZD5122 in urine</measure>
    <time_frame>Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the effect of AZD5122 on circulating neutrophils</measure>
    <time_frame>Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 96 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile: assessment of various pharmacodynamic measures</measure>
    <time_frame>Samples collected at Visit 2 from pre-dose and at regular protocol defined intervals up to 48 hours post-dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5122 oral suspension (part A and B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral suspension (part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5122 oral and IV infusion (part B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5122</intervention_name>
    <description>A single dose of oral suspension</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single dose of oral suspension</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5122</intervention_name>
    <description>A single intravenous infusion</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent.

          -  Normal physical examination, laboratory values, blood pressure and pulse

          -  Healthy male caucasian subjects

        Exclusion Criteria:

          -  Subjects must not have any history of gastrointestinal, hepatic or renal disease, or
             any other condition known to interfere with how drugs are absorbed, used or eliminated
             by the body.

          -  Subjects must not have abnormal blood or urine tests for hsCRP, circulating
             neutrophils, haematocrit, haemoglobin or renal function

          -  Subjects must not have crystals or more than a trace of blood in their urine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Sparrow, BSc, BMedSci, BM,BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottinghamshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>December 3, 2009</last_update_submitted>
  <last_update_submitted_qc>December 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>AZD5122</keyword>
  <keyword>single oral dose</keyword>
  <keyword>phase 1</keyword>
  <keyword>Healthy volunteer phase 1 study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

